Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akhtar Ashfaq

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Advances in Chronic Kidney Disease|December 12, 2018
Leadership in the Industry Arena: Nephrologists in Nonclinical Leadership RolesAkhtar Ashfaq
Expert Opinion on Pharmacotherapy|October 6, 2006
Emerging strategies for lowering serum phosphorous in patients with end-stage renal diseaseAkhtar Ashfaq, Michael Gitman, Pravin C Singhal
BMC Nephrology|May 21, 2011
Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysisIrfan Khan, Mahesh Krishnan, Anupam Kothawala, et al.
Kidney Diseases (Basel, Switzerland)|July 27, 2023
Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney DiseaseStephen A Strugnell, Philipp Csomor, Akhtar Ashfaq, et al.
Journal of Medical Economics|November 16, 2019
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKDKamyar Kalantar-Zadeh, Christopher S Hollenbeak, Roy Arguello, et al.
Forum for Health Economics & Policy|March 6, 2020
Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-DialysisSophie Snyder, Christopher S Hollenbeak, Kamyar Kalantar-Zadeh, et al.
American Journal of Nephrology|May 13, 2022
Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary HyperparathyroidismCharles W Bishop, Stephen A Strugnell, Philipp Csomor, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 14, 2025
Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicityCharles W Bishop, John Choe, Stephen A Strugnell, et al.
American Journal of Nephrology|March 18, 2019
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney DiseaseStephen A Strugnell, Stuart M Sprague, Akhtar Ashfaq, et al.
Kidney International Reports|April 29, 2021
Testing Patterns for CKD-MBD Abnormalities in a Sample US PopulationJames B Wetmore, Yuanyuan Ji, Akhtar Ashfaq, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Advances in Chronic Kidney Disease|December 12, 2018
Leadership in the Industry Arena: Nephrologists in Nonclinical Leadership RolesAkhtar Ashfaq
Expert Opinion on Pharmacotherapy|October 6, 2006
Emerging strategies for lowering serum phosphorous in patients with end-stage renal diseaseAkhtar Ashfaq, Michael Gitman, Pravin C Singhal
BMC Nephrology|May 21, 2011
Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysisIrfan Khan, Mahesh Krishnan, Anupam Kothawala, et al.
Kidney Diseases (Basel, Switzerland)|July 27, 2023
Evaluation of Therapies for Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Chronic Kidney DiseaseStephen A Strugnell, Philipp Csomor, Akhtar Ashfaq, et al.
Journal of Medical Economics|November 16, 2019
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKDKamyar Kalantar-Zadeh, Christopher S Hollenbeak, Roy Arguello, et al.
Forum for Health Economics & Policy|March 6, 2020
Cost-Effectiveness and Estimated Health Benefits of Treating Patients with Vitamin D in Pre-DialysisSophie Snyder, Christopher S Hollenbeak, Kamyar Kalantar-Zadeh, et al.
American Journal of Nephrology|May 13, 2022
Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary HyperparathyroidismCharles W Bishop, Stephen A Strugnell, Philipp Csomor, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 14, 2025
Effect of race, gender and age on intrinsic diurnal variation of serum calcifediol: Insights into vitamin D toxicityCharles W Bishop, John Choe, Stephen A Strugnell, et al.
American Journal of Nephrology|March 18, 2019
Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney DiseaseStephen A Strugnell, Stuart M Sprague, Akhtar Ashfaq, et al.
Kidney International Reports|April 29, 2021
Testing Patterns for CKD-MBD Abnormalities in a Sample US PopulationJames B Wetmore, Yuanyuan Ji, Akhtar Ashfaq, et al.
Pageof 3